6 news items
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
CELU
19 Apr 24
develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies
Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024
CELU
18 Apr 24
availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
CELU
15 Apr 24
needs for effective, accessible, and affordable therapies. Forward-Looking Statements
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
CELU
8 Apr 24
develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
CELU
20 Mar 24
for effective, accessible and affordable therapies. Forward-Looking StatementsThis press release
pnzjowcfo25rt3 lozmtx5b2hthmtte28bfcahut143ydr3ya355y4d
CELU
14 Mar 24
availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies
- Prev
- 1
- Next